FIERCELY
FOCUSED

on the development of novel
treatments for patients with
B-cell malignancies and
autoimmune diseases.

Learn
about us

Explore our
pipeline

investor
Information

Read our
publications

Latest News

TG Therapeutics Announces Phase I Data Presentation for TG-1701, a Once-Daily BTK Inhibitor, as a Single Agent and in Triple Combination with Ublituximab and Umbralisib (U2), at th...

Proprietary triplet of U2 plus TG-1701 (BTK inhibitor) induced 86% ORR (6 of 7) in patients with relapsed/refractory NHL and CLL at the lowest dose of TG-1701 tested Single agent TG-1701 induced responses at multiple dose levels (including the lowest dose tested) across multiple B-cell diseases

Read More >

2 Gansevoort Street, 9th Floor
New York, NY 10014

Email Us (212) 554-4484